奈达铂联合希罗达在晚期食管癌治疗中的临床效果观察

Observation of clinical effect by nedaplatin combined with xeloda in the treatment of advanced esophageal cancer

目的观察奈达铂联合希罗达在晚期食管癌治疗中的临床效果,分析其临床应用价值。方法 48例晚期食管癌患者,根据治疗方法不同分为实验组和对照组,每组24例。对照组患者采取顺铂联合希罗达进行治疗,实验组患者采取奈达铂联合希罗达进行治疗,观察并对比两组患者治疗后的临床效果以及不良反应发生率。结果实验组患者总有效率为58.3%,病情进展率为20.8%;对照组患者总有效率为50.0%,病情进展率为20.8%。两组患者总有效率和病情进展率比较差异均无统计学意义(P>0.05)。两组患者治疗期间主要出现恶心呕吐、肾功能损害、肝功能损害、口腔炎以及皮炎、白细胞计数减少、血小板计数减少等不良反应。实验组血液毒性(白细胞计数减少、血小板计数减少)发生率稍高于对照组,但差异无统计学意义(P>0.05);实验组恶心呕吐、肝肾功能损害、口腔炎以及皮炎等不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论奈达铂联合希罗达治疗晚期食管癌能够明显降低不良反应的发生率,安全性较高,具有一定的临床意义,值得在临床上大力推广应用。

Objective To observe clinical effect by nedaplatin combined with xeloda in the treatment of advanced esophageal cancer, and to analyze its clinical application value. Methods A total of 48 patients with advanced esophageal cancer were divided by different treatment measures into experimental group and control group, with 24 cases in each group. The control group received cisplatin combined with xeloda for treatment, and the experimental group received nedaplatin combined with xeloda for treatment. Observation was made on clinical effects and incidence of adverse reactions between the two groups after treatment. Results The experimental group had total effective rate as 58.3% and disease progress rate as 20.8%, and the control group had total effective rate as 50.0% and disease progress rate as 20.8%. There were no statistically significant differences of total effective rate and disease progress rate between the two groups（P〈0.05）. Main adverse reactions in the two groups during treatment included nausea and vomiting, renal function damage, liver function damage, stomatitis, dermatitis, decreased white blood cell count and blood platelet count. The experimental group had slightly higher incidence of hematotoxicity（decreased white blood cell count and blood platelet count）than the control group, while their difference had no statistical significance（P〈0.05）. The experimental group had obviously lower incidences of nausea and vomiting, liver function damage, stomatitis and dermatitis as adverse reactions than the control group, and the difference had statistical significance（P〈0.05）. Conclusion Combination of nedaplatin and xeloda in treating advanced esophageal cancer can remarkably decrease incidence of adverse reactions, along with high safety and certain clinical significance. This method is worth widely clinical promotion and application.